Mitochondrial replacement in an iPSC model of Leber’s hereditary optic neuropathy

Raymond C.B. Wong1,2, Shiang Y. Lim3, Sandy S.C. Hung1,2, Stacey Jackson1,2, Shahnaz Khan1,2, Nicole J. Van Bergen1,2, Elisabeth De Smit1,2, Helena H. Liang1,2, Lisa S Kearns1,2, Linda Clarke1,2, David A. Mackey4,5, Alex W. Hewitt1,2,5, Ian A. Trounce1,2,* , Alice Pébay1,2,*

1 Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia
2 Department of Surgery, the University of Melbourne, Melbourne, Australia
3 O’Brien Institute Department, St Vincent’s Institute of Medical Research, Victoria, Australia
4 Centre for Ophthalmology and Vision Science, University of Western Australia, Lions Eye Institute, Nedlands, Australia
5 School of Medicine, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
* Co-senior authors

Correspondence to: Raymond C.B. Wong, Alice Pébay; email: wongcb@unimelb.edu.au, apebay@unimelb.edu.au

Keywords: Leber’s hereditary optic neuropathy, disease model, induced pluripotent stem cells, retinal ganglion cells, cybrid

Received: March 25, 2017 Accepted: April 23, 2017 Published: April 29, 2017

Copyright: Wong et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

ABSTRACT

Cybrid technology was used to replace Leber hereditary optic neuropathy (LHON) causing mitochondrial DNA (mtDNA) mutations from patient-specific fibroblasts with wildtype mtDNA, and mutation-free induced pluripotent stem cells (iPSCs) were generated subsequently. Retinal ganglion cell (RGC) differentiation demonstrates increased cell death in LHON-RGCs and can be rescued in cybrid corrected RGCs.

INTRODUCTION

Patient somatic cells can be reprogrammed into iPSCs, by ectopic expression of a combination of reprogramming factors [1, 2]. These cells can subsequently be differentiated into cell types of interest, providing a platform for disease modeling, drug screening and gene therapy. In recent years, the field of iPSC disease modeling has focused on the use of isogenic control, i.e. by correcting the disease-causing mutation(s) to verify the disease phenotypes observed in the iPSC model.

Gene editing technologies, such as TALEN or CRISPR/Cas9, emerged as tools to establish isogenic iPSC controls for nuclear gene mutations. However, the difficulty of genetically manipulating mtDNA represents an obstacle for generating iPSC isogenic controls to model mtDNA diseases. Mutations in mtDNA can be heteroplasmic (mutated mtDNA coexists with wild-type mtDNA) or homoplasmic (all mtDNA copies are mutated). iPSCs have been utilised to model mitochondrial diseases with mtDNA heteroplasmy [3]. Interestingly, mutated mtDNA heteroplasmy has been reported to segregate during iPSC reprogramming, similar to the mtDNA genetic bottleneck phenomenon observed during early embryogenesis. In Mitochondrial Encephalomyopathy Lactic Acidosis and Stroke-like episodes (MELAS) [4], Pearson Syndrome [5] and diabetes mellitus [6], iPSC reprogramming yielded both mutant mtDNA-rich iPSC clones and mutation-free iPSC clones. However, this approach would not be feasible for iPSC modeling of homoplasmic mtDNA disease, such as LHON.

LHON is characterized by loss of the RGCs [7]. In European populations, approximately 1 in 9,000 is a LHON carrier and it affects approximately 1 in 30,000 individuals, causing sudden visual loss predominantly [8]. All LHON cases are caused by mtDNA mutations
that encode for the mitochondrial Complex I subunits [9, 10]. These homoplasmic mutations are shown to disrupt the activity of Complex I, leading to a decrease in bioenergetic production and an increased level of oxidative stress [11]. However, the precise mechanism for disease progression in LHON remains unknown. Here we report the use of iPSCs to model LHON, and demonstrate generation of isogenic iPSC controls by replacing LHON mtDNA using cybrid technology.

RESULTS

We previously reported on the generation and characterisation of LHON iPSCs [12]. For this study, we utilised iPSCs from a healthy control (MRU11780), and a LHON patient (LHON Q1-4) with homoplasmic double mtDNA mutations m.4160T>C and m.14484T>C which affected the MT-ND1 and MT-ND6 genes respectively [12]. This LHON patient exhibited

![Diagram of cybrid generation](image)

**Figure 1. Using cybrid transfer to generate mutation-free LHON fibroblasts and iPSCs.** (A) Diagram of cybrid generation. Fibroblasts were pre-treated with the mitochondrial toxin rhodamine 6-G (R6G) then fused with healthy donor mitochondria obtained from normal keratinocytes. On day 29-32, proliferating colonies were picked and expanded.
“LHON plus” phenotype, with clinical features including optic nerve atrophy, juvenile encephalopathy and peripheral neuropathy [13]. To generate an isogenic control for iPSC modeling, we utilised the cybrid technique to replace the mutant mtDNA in LHON fibroblasts. LHON fibroblasts were pre-treated with rhodamine 6-G to disable the transmission of endogenous mtDNA, followed by fusion with donor mitochondria obtained from wild-type keratinocytes (Fig. 1A). After 27 days post-fusion, proliferating fibroblast colonies that are indicative of successful mitochondrial replacement were isolated and expanded (Fig. 1B). Out of 12 clones screened, we identified 1 cybrid clone with the donor keratinocyte mitochondria (Fig. 1B). In contrast, no proliferating fibroblast colony mitochondrial replacement were isolated and expanded fibroblast colonies that are indicative of successful correction with no detectable mutations at m.4160 and m.14484 (Fig. 1C, Supplementary Fig. 1). Further characterization demonstrated that the cybrid iPSCs from the cybrid fibroblasts using the episomal method. Following reprogramming, three clones of cybrid iPSCs (CYB iPSC c1, CYB iPSC c2, CYB iPSC c3) were selected for this study. Importantly, all cybrid iPSC clones retained mtDNA correction with no detectable mutations at m.4160 and m.14484 (Fig. 1C, Supplementary Fig. 1). Further characterization demonstrated that the cybrid iPSCs expressed the pluripotent markers OCT-4 and TRA-1-60 (Fig. 1E, Supplementary Fig. 2). The derived cybrid iPSCs were also differentiated into cells of the three germ layers in vitro by embryoid body formation and in vivo by teratoma formation (Fig. 1F, Supplementary Figs. 2 and 3). Copy number variation analysis indicat-
ed no chromosomal abnormalities in the derived cybrid iPSC clones (Fig. 1G, Supplementary Fig. 4). Together, these results demonstrate the feasibility of using the cybrid technique to generate isogenic iPSC controls for mtDNA disease modeling.

Finally, we assessed the effect of the LHON mtDNA mutations in iPSC-derived RGCs. Control, LHON and cybrid iPSCs were directed to differentiate into RGCs by a stepwise differentiation method that we recently published, which demonstrated an enriched population of functional RGCs [14]. Three iPSC clones per patient were used and all clones were able to differentiate into RGCs with similar efficiency (Fig. 2A). Following RGC enrichment using MACS, TUNEL analysis revealed an increased level of apoptosis in LHON RGCs, from 13.6 ± 1.9% in control RGCs to 56.1 ± 6.8% in LHON RGCs (Fig. 2B). Importantly, this effect was reverted in the cybrid corrected RGCs, with the apoptosis level returned to control levels (Fig. 2B, 12.9 ± 4.4%), demonstrating that the increased susceptibility to cell death observed in LHON-RGCs is a direct consequence of LHON mtDNA mutations. Mitochondrial dysfunction in RGCs was then assessed using MitoSOX, which measures the levels of mitochondrial superoxide, as an indication of mitochondrial oxidative stress. Despite a trend of an increased superoxide levels in LHON RGCs compared to control RGCs, this difference in mitochondrial superoxide levels was not statistically significant, possibly due to high variations observed amongst the iPSC clones. Lower superoxide levels were also observed in corrected cybrid lines compared to LHON RGCs (Fig. 2C). Together these results suggest that the higher apoptosis observed in the LHON RGCs cannot be explained by elevated mitochondrial superoxide alone. Future studies to investigate other defects in LHON RGCs, such as ATP deficiency [15] or mitochondrial biogenesis [16], will help elucidate the mechanism underlying penetrance and disease progression of LHON.

DISCUSSION

The recent development of mitochondrial replacement therapy using pronuclear transfer offers exciting prospects to correct mtDNA mutations in the early human embryo [17]. However, pronuclear transfer is technically challenging, especially in cells of small size, and requires specialised equipment. Here, we describe for the first time a cybrid approach to correct mtDNA mutations in an iPSC disease model. Compared to pronuclear transfer, the cybrid technique is easier to perform and can be adapted to generate an isogenic control for iPSC models of homoplasmic mtDNA diseases. Reduction of mutant mtDNA load, rather than complete replacement of mutant mtDNA with wild-type mtDNA, might be sufficient for phenotypic rescue in iPSC isogenic controls. In support of this, previous studies have shown that selective elimination of mutant mtDNA by mitochondria-targeted TALEN can reduce the mutant mtDNA loads and restore the mitochondrial dysfunction [18]. Very recently, zinc fingers were also used for the successful replacement of heteroplasmic mtDNA [19]. Our results show an increased susceptibility to apoptosis in LHON iPSC-derived RGCs. Importantly, apoptosis was returned to normal levels in the cybrid-corrected RGCs, hence demonstrating that the increased susceptibility to cell death observed in RGCs is a direct consequence of LHON mtDNA mutations.

In summary, our approach shows the advantage of using LHON patient-derived iPSCs and their isogenic cybrid control as a platform for the study of the fundamental mechanisms underlying LHON pathogenesis. Moreover, the cybrid technique provides a feasible strategy to correct mtDNA mutations in iPSC models, which could be applied to model other mtDNA diseases.

MATERIALS AND METHODS

Ethics

All experimental work performed in this study was approved by the Human Research Ethics Committees of the Royal Victorian Eye and Ear Hospital (11/1031H) and the University of Melbourne (0605017) [20,21], and with the Animal Ethics Committee of St Vincent’s Hospital (002/14), in accordance with the requirements of the National Health & Medical Research Council of Australia and conformed with the Declarations of Helsinki.

Cell culture

Cell lines used in this study consisted of control (MRU11780 [12]), LHON (LHON Q1-4 carrying m.14484 & m.4160 mtDNA mutations [12]) and cybrid-corrected lines. Fibroblasts were cultured in DMEM medium supplemented with 10% fetal calf serum, 1 x L-glutamine, 0.1 mM non-essential amino acids and 0.5× penicillin/streptomycin (all from Invitrogen). iPSC lines were cultured on mitotically inactivated mouse embryonic fibroblasts feeders in the presence of DMEM/F-12 medium supplemented with 1 x GlutaMAX, 20% knockout serum replacement, 10 ng/ml basic fibroblast growth factor, 0.1 mM non-essential amino acids, 100 μM β-mercaptoethanol and penicillin/streptomycin (all from Invitrogen) and passaged weekly as previously described [12].
Cybrid generation

Cybrid transfer was performed as described [22,23]. Briefly, human epidermal keratinocytes (System Bioscience) were used as donor by enucleation using cytochalasin B treatment and high speed centrifugation. LHON Q1-4 fibroblasts were pre-treated with 2.5µg/ml rhodamine 6-G for 5 days, before fusion with donor cell cytoplasts using polyethylene glycol. On the next day, fused cells were replated and allowed to culture for up to 32 days. Proliferating colonies were picked and expanded using cloning cylinders (Corning). Isolated fibroblast clones were genotyped for mtDNA mutations at mt.4160 and mt.14484 to screen for successful mitochondrial replacement.

Microsatellite analysis

Microsatellite analysis was performed by the Australian Genome Research Facility, using 12 polymorphic markers from the Applied Biosystems linkage mapping set. The markers utilised are D2S2211, D2S125, D2S337, D3S1267, D6S257, D8S284, D11S904, D11S4151, D12S78, D12S345, D14S283 and D17S1852. Hierarchical clustering and heatmap is generated using R.

iPSC generation and characterisation

Reprogramming of cybrid-corrected fibroblasts was performed as described in [24]. Episomal vectors expressing OCT4, SOX2, KLF4, L-MYC, LIN28 and shRNA against p53 were gifts from Shinya Yamanaka (Addgene #27077, 27078, 27080). In vitro differentiation of iPSCs was performed by embryoid bodies and characterised as described in [12]. In vivo teratoma assay was performed by transplanting iPSCs into a vascularized tissue engineering chamber in immuno-deficient rats, as described in [24]. Histological analysis was performed on the teratoma samples after 4 weeks. Copy number variation (CNV) analysis of original fibroblasts and iPSCs was performed using Illumina HumanCore Beadchip arrays. CNV analyses were performed using PennCNV with default parameter settings [25]. Chromosomal aberrations were deemed to involve at least 10 contiguous single nucleotide polymorphisms (SNPs) or a genomic region spanning at least 1MB [25,26].

RGC differentiation

iPSCs were directed for retinal differentiation and enriched for RGCs using MACS THY1.1 microbeads (Miltenyi Biotech) as described in our previous study [14]. On day 30, RGC differentiation efficiency is determined as described previously [14].

Immunohistochemistry

Standard immunohistochemistry procedure was performed using mouse anti-OCT3/4 (#SC-5279, Santa Cruz Biotechnology), mouse anti-TRA-1-60 (#MAB4360, Millipore), mouse anti-NESTIN (#AB22035, Abcam), mouse anti-alpha-fetoprotein (AFP, #ST1673, Millipore), mouse anti-smooth muscle actin (SMA, #MAB1420, R&D systems). Cells were then immunostained with the appropriate conjugated secondary antibodies (Alexa Fluor 488, Molecular probes-Invitrogen). Nuclei were counter-stained with DAPI (Invitrogen). Immunohistochemistry for human cells was performed using rabbit anti-Ku80 (#AB80592, Abcam) followed by biotinylated goat anti-rabbit secondary antibody (Vector Laboratories) and avidin-biotinylated-peroxidase complex (Vector Laboratories). Peroxidase activity was visualised with diaminobenzidine chromogen (Dako) and sections were counterstained with hematoxylin. Specificity of the staining was verified by the absence of staining in negative controls consisting of the appropriate negative control immunoglobulin fraction.

Mitochondrial superoxide measurement

Quantification of mitochondrial superoxide was performed on day 30 iPSC-derived RGCs using MitoSOX (Invitrogen) according to the manufacturer’s instructions. Briefly, trypsinized cells were stained with Mitosox for 10 minutes at 37°C. Subsequently, samples were processed by flow cytometry using the MACSquant (Miltenyi). The median fluorescence intensity was determined using the MACSQuantify software and normalized to unstained control. At least 83,000 cells were processed by FACS.

Apoptosis assay

TUNEL assay was performed on day 37-41 iPSC-derived RGCs using the In situ Cell death detection kit (Roche) following manufacturer’s instructions. Floating apoptotic bodies were collected and the enriched RGCs were harvested by trypsinization. Quantitation of TUNEL positive cells was measured by flow cytometry using the MACSquant (Miltenyi). Apoptosis was assessed in basal conditions, without addition of any stressor or inducer of apoptosis. Generally, a minimum of 10,000 cells per clone were processed by FACS. In clones where <10,000 cells were obtained, experimental repeats were performed to obtain >10,000 cells.

Statistical analysis

All statistical analyses and graphical data were generated using Graphpad Prism software (v5.04,
www.graphpad.com) or in the R statistical environment (v3.1.2, https://cran.r-project.org/). Statistical methods utilised were One-way ANOVA followed Dunnett’s multiple comparisons test for multiple comparison. Statistical significance was established as * p<0.05 and **p<0.01.

Abbreviations

Cybrid: cyb; induced pluripotent stem cells: iPSCs; Leber hereditary optic neuropathy: LHON; Mitochondrial Encephalomyopathy Lactic Acidosis and Stroke-like episodes: MELAS; mitochondrial: mt; retinal ganglion cells: RGCs.

AUTHOR CONTRIBUTIONS

RCBW: concept and design, financial support, collection and/or assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript. SJ, SK, SYL, SSCH, NJvB, MD, EDS, HHL, LK, LC, DM: collection and/or assembly of data, data analysis and interpretation, final approval of manuscript. AWH, IAT: concept and design, financial support, data analysis and interpretation, final approval of manuscript. AP: concept and design, financial support, data analysis and interpretation, manuscript writing, final approval of manuscript.

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

FUNDING

This work was supported by grants from the National Health and Medical Research Council (NHMRC, RCBW, 1084256), the Australian Mitochondrial Disease Foundation (RCBW, AWH, IAT, AP), the Brockhoff foundation (IAT, AP) the University of Melbourne (RCBW, AP), and the Ophthalmic Research Institute of Australia (RCBW, NJvB, AP). AWH is supported by a NHMRC Practitioner Fellowship (APP1103329), AP by an Australian Research Council Future Fellowship (FT140100047) and a Peggy and Leslie Cranbourne Foundation Fellowship (RCBW) as well as a Medical Advances Without Animals Trust Fellowship. The Centre for Eye Research Australia receives operational infrastructure support from the Victorian Government.

REFERENCES

1. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131:861–72. doi: 10.1016/j.cell.2007.11.019
2. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007; 318:1917–20. doi: 10.1126/science.1151526
3. Xu X, Duan S, Yi F, Ocampo A, Liu GH, Izpisua Belmonte JC, Belmonte JC. Mitochondrial regulation in pluripotent stem cells. Cell Metab. 2013; 18:325–32. doi: 10.1016/j.cmet.2013.06.005
4. Folmes CD, Martinez-Fernandez A, Perales-Clemente E, Li X, McDonald A, Oglesbee D, Hrstka SC, Perez-Terzic C, Terzic A, Nelson TJ. Disease-causing mitochondrial heteroplasmy segregated within induced pluripotent stem cell clones derived from a patient with MELAS. Stem Cells. 2013; 31:1298–308. doi: 10.1002/stem.1389
5. Cherry AB, Gagne KE, McLoughlin EM, Bacei A, Gorman B, Hartung O, Miller JD, Zhang J, Zon RL, Ince TA, Neufeld EJ, Lerou PH, Fleming MD, et al. Induced pluripotent stem cells with a mitochondrial DNA deletion. Stem Cells. 2013; 31:1287–97. doi: 10.1002/stem.1354
6. Fujikura J, Nakao K, Sone M, Noguchi M, Mori E, Naito M, Taura D, Harada-Shiba M, Kishimoto I, Watanabe A, Asaka I, Hosoda K, Nakao K. Induced pluripotent stem cells generated from diabetic patients with mitochondrial DNA A3243G mutation. Diabetologia. 2012; 55:1689–98. doi: 10.1007/s00125-012-2508-2
7. Lopez Sanchez MI, Crowston JG, Mackey DA, Trounce IA. Emerging Mitochondrial Therapeutic Targets in Optic Neuropathies. Pharmacol Ther. 2016; 165:132–52. doi: 10.1016/j.pharmthera.2016.06.004
8. Yu-Wai-Man P, Griffiths PG, Chinnery PF. Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies. Prog Retin Eye Res. 2011; 30:81–114. doi: 10.1016/j.preteyeres.2010.11.002
9. Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza AM, Elsaq LJ 2nd, Nikoskelainen EK. Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy. Science. 1988; 242:1427–30. doi: 10.1126/science.3201231
10. Mackey DA, Oostra RJ, Rosenberg T, Nikoskelainen E, Bronte-Stewart J, Poulton J, Harding AE, Govan G, Bolhuis PA, Norby S. Primary pathogenic mtDNA mutations in multigeneration pedigrees with Leber hereditary optic neuropathy. Am J Hum Genet. 1996; 59:481–85.
11. Kirches E. LHON: Mitochondrial Mutations and More. Curr Genomics. 2011; 12:44–54. doi: 10.2174/138920211794520150

12. Hung SS, Van Bergen NJ, Jackson S, Liang H, Mackey DA, Hernández D, Lim SY, Hewitt AW, Trounce I, Pébay A, Wong RC, Raymond W. Study of mitochondrial respiratory defects on reprogramming to human induced pluripotent stem cells. Aging (Albany NY). 2016; 8:945–57. doi: 10.18632/aging.100950

13. Mackey DA. Three subgroups of patients from the United Kingdom with Leber hereditary optic neuropathy. Eye (Lond). 1994; 8:431–36. doi: 10.1038/eye.1994.102

14. Gill KP, Hung SS, Sharov A, Lo CY, Needham K, Lidgerwood GE, Jackson S, Crombie DE, Nayagam BA, Cook AL, Hewitt AW, Pébay A, Wong RC. Enriched retinal ganglion cells derived from human embryonic stem cells. Sci Rep. 2016; 6:30552. doi: 10.1038/srep30552

15. Baracca A, Solaini G, Sgarbi G, Lenaz G, Baruzzi A, Schapira AH, Martinuzzi A, Carelli V. Severe impairment of complex I-driven adenosine triphosphate synthesis in leber hereditary optic neuropathy cybrids. Arch Neurol. 2005; 62:730–36. doi: 10.1001/archneur.62.5.730

16. Giordano C, Iommarini L, Giordano L, Maresca A, Pisano A, Valentino ML, Caporali L, Liguori R, Deceglie S, Roberti M, Fanelli F, Fracasso F, Ross-Cisneros FN, et al. Efficient mitochondrial biogenesis drives incomplete penetrance in Leber’s hereditary optic neuropathy. Brain. 2014; 137:335–53. doi: 10.1093/brain/awt343

17. Hyslop LA, Blakeley P, Craven L, Richardson J, Fogarty NM, Fragouli E, Lamb M, Wamaitha SE, Prathalingam N, Zhang Q, O’Keefe H, Takeda Y, Arizzi L, et al. Towards clinical application of pronuclear transfer to prevent mitochondrial DNA disease. Nature. 2016; 534:383–86. doi: 10.1038/nature18303

18. Hashimoto M, Bacman SR, Peralta S, Falk MJ, Chomyn A, Chan DC, Williams SL, Moraes CT. MitOTALEN: A General Approach to Reduce Mutant mtDNA Loads and Restore Oxidative Phosphorylation Function in Mitochondrial Diseases. Mol Ther. 2015; 23:1592–99. doi: 10.1038/mt.2015.126

19. Gammage PA, Gaude E, Van Haute L, Rebello-Giromar P, Jackson CB, Rorbach J, Pekalski ML, Robinson AJ, Charpentier M, Concordet JP, Frezza C, Minczuk M. Near-complete elimination of mutant mtDNA by iterative or dynamic dose-controlled treatment with mtZFNs. Nucleic Acids Res. 2016; 44:7804–16. doi: 10.1093/nar/gkw676

20. McCaughey T, Chen CY, De Smit E, Rees G, Fenwick E, Kearns LS, Mackey DA, MacGregor C, Munsie M, Cook AL, Pébay A, Hewitt AW. Participant understanding and recall of informed consent for induced pluripotent stem cell biobanking. Cell Tissue Bank. 2016; 17:449–56. doi: 10.1007/s10561-016-9563-8

21. McCaughey T, Liang HH, Chen C, Fenwick E, Rees G, Wong RC, Vickers JC, Summers MJ, MacGregor C, Craig JE, Munsie M, Pébay A, Hewitt AW. An Interactive Multimedia Approach to Improving Informed Consent for Induced Pluripotent Stem Cell Research. Cell Stem Cell. 2016; 18:307–08. doi: 10.1016/j.stem.2016.02.006

22. Trounce I, Wallace DC. Production of transmitchondrial mouse cell lines by cybrid rescue of rhodamine-6G pre-treated L-cells. Somat Cell Mol Genet. 1996; 22:81–85. doi: 10.1007/BF02374379

23. Williams AJ, Murrell M, Brammah S, Minchenko J, Christodoulou J. A novel system for assigning the mode of inheritance in mitochondrial disorders using cybrids and rhodamine 6G. Hum Mol Genet. 1999; 8:1691–97. doi: 10.1093/hmg/8.9.1691

24. Piao Y, Hung SS, Lim SY, Wong RC, Ko MS. Efficient generation of integration-free human induced pluripotent stem cells from keratinocytes by simple transfection of episomal vectors. Stem Cells Transl Med. 2014; 3:787–91. doi: 10.5966/sctm.2013-0036

25. Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SF, Hakonarson H, Bucan M. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res. 2007; 17:1665–74. doi: 10.1101/gr.6861907

26. Kilipinen H, Helena K, Angela G, Andreas L, Vackar A, Sofie A, Sendu B, Dalila B, Casale FP, Oliver C, Petr D, Adam F, Peter H, et al. Common genetic variation drives molecular heterogeneity in human iPSCs. bioRxiv. 2016. doi: 10.1101/055160